Epoprostenol

證據等級: L5

預測適應症: 0 個

Epoprostenol (DB01240): Pulmonary Arterial Hypertension — Evidence Pack Incomplete, Assessment Pending

One-Sentence Summary

Epoprostenol (prostacyclin, PGI₂) is a synthetic vasodilator and platelet aggregation inhibitor classically used in the management of pulmonary arterial hypertension (PAH). However, the current Evidence Pack contains no TxGNN prediction output and no Denmark market authorisation records, meaning a full drug repurposing evaluation cannot be completed at this stage. This report documents the identified data gaps and recommends a structured remediation pathway before proceeding.

Quick Overview

Item	Content
Original Indication	Pulmonary arterial hypertension (based on general pharmacological knowledge; not supplied in evidence pack)
Predicted New Indication	No prediction data available
TxGNN Prediction Score	No prediction data available
Evidence Level	Not assessable
Denmark Market Status	Not recorded (0 licences on file — likely a data collection gap; EU centralised authorisations exist)
Number of Marketing Authorisations	0 (on file)
Recommended Decision	Hold — critical data gaps must be resolved first

Why This Report Cannot Be Completed Yet

The TxGNN model prediction pipeline did not return any repurposing candidates for Epoprostenol in this Evidence Pack (version v4, data cut-off 2026-04-05). Two high-severity data gaps have been formally logged:

Gap ID	Category	Missing Item	Severity	Impact
DG001	Drug Level	Danish Medicines Agency (Laegemiddelstyrelsen) / EMA approved warnings and contraindications	Blocking	Cannot complete S1 safety screening
DG002	Drug Level	Mechanism of action (MOA)	High	Cannot perform mechanistic plausibility analysis for any predicted indication

Until these gaps are resolved and the TxGNN pipeline is re-run with complete input data, a meaningful repurposing evaluation cannot be generated.

Denmark Market Information

The evidence pack records zero marketing authorisations for Epoprostenol in Denmark. This is inconsistent with publicly known regulatory status: Epoprostenol is available in the EU under centralised EMA procedures (e.g., Flolan, Veletri), which automatically confer authorisation in all EU/EEA member states including Denmark.

This strongly suggests a data collection failure rather than true absence from the Danish market.

Expected Authorisation	Product Name	Dosage Form	Note
EMA centralised (verify via EMA EPAR database)	Flolan	Powder and solvent for solution for infusion	PAH — verify current status at ema.europa.eu
EMA centralised (verify via EMA EPAR database)	Veletri	Powder for solution for infusion	PAH — verify current status at ema.europa.eu

Action required: Query the EMA Product Database and the Laegemiddelstyrelsen produktresume database to retrieve current authorisation numbers, SmPC, and approved indications.

Safety Considerations

No safety data was retrieved for this evidence pack. All key warnings, contraindications, and drug interaction fields are absent.

Please refer to the approved Summary of Product Characteristics (SmPC) — available via the EMA EPAR for Flolan or Veletri — for complete safety information before any clinical assessment.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Epoprostenol is missing both the TxGNN prediction output and Denmark/EMA regulatory safety data, making it impossible to assess any repurposing hypothesis or evaluate risk–benefit at this stage.

To proceed, the following is needed:

Re-run the TxGNN pipeline for DB01240 and confirm that predicted_indications is populated with at least one candidate before generating a full report.
Retrieve MOA data (DG002) from DrugBank API (DrugBank ID: DB01240) — Epoprostenol is expected to act via prostacyclin receptor (IP receptor) agonism, leading to cAMP-mediated vasodilation and inhibition of platelet aggregation; confirm and populate original_moa.
Retrieve SmPC warnings and contraindications (DG001) from the EMA EPAR documents for Flolan/Veletri; parse and populate safety.key_warnings and safety.contraindications.
Correct the Denmark regulatory record by querying the EMA centralised authorisation database and the Laegemiddelstyrelsen produktresume register; update taiwan_regulatory.market_status, total_licenses, and licenses[].
Re-submit the completed Evidence Pack to regenerate a full evaluation report with predicted indications, mechanistic rationale, clinical trial evidence, and a final Go / Proceed with Guardrails recommendation.

This report is generated for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.